Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veliparib - Abbvie

Drug Profile

Veliparib - Abbvie

Alternative Names: ABT 888; NSC 737664

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories; University of Alabama at Birmingham
  • Developer Abbott Laboratories; AbbVie; Georgetown University; National Cancer Institute (USA); Northwestern University; University of Alabama at Birmingham
  • Class Amides; Antineoplastics; Benzimidazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Fallopian tube cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Colorectal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours; Testicular cancer
  • Phase I/II Glioma; Head and neck cancer; Small cell lung cancer
  • No development reported Lymphoma; Multiple myeloma; Prostate cancer
  • Discontinued Liver cancer

Most Recent Events

  • 25 Jan 2024 AbbVie completes a phase III trial in HER2-negative-breast-cancer (Combination therapy, Late-stage disease) in USA, Austria, Australia, Belgium, Finland, Portugal, Hungary, Latvia, Spain, Puerto Rico, Ukraine, Turkey, Taiwan, South Africa, Singapore, Russia, Romania, Poland, Norway, Netherlands, Mexico, Lithuania, South Korea, France, Israel, Germany, Estonia, Denmark, Czech Republic, Colombia, Chile, Canada, Belarus, UK, Sweden and Italy (PO) (NCT02163694) (EudraCT2014-000345-70)
  • 30 Oct 2023 Abbvie terminates a phase III VELIA trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Combination therapy, First-line therapy, Late-stage disease) in USA, Australia, Brazil, Denmark, Israel, Japan, South korea, New Zealand, Poland, Spain and United Kingdom (PO) due to business decision and not due to patient safety (NCT02470585)
  • 20 Sep 2023 National Cancer Institute completes a phase II trial in Rectal cancer (Neoadjuvant therapy, Late-stage disease, First-line therapy, Combination therapy) in USA and Puerto Rico (PO) (NCT02921256)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top